Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Sildenafil for Pulmonary Arterial Hypertension

Bhogal, Sukhdeep MD1; Khraisha, Ola MD1; Al Madani, Mohammad MD1; Treece, Jennifer MD, MBA1; Baumrucker, Steven J. MD2; Paul, Timir K. MD, PhD1,*

doi: 10.1097/MJT.0000000000000766
Therapeutic Opinions

Pulmonary hypertension is a life-threatening illness with debilitating physical and emotional consequences. The progression of this devastating disease is characterized by a continuous increase in pulmonary vascular resistance, which results in elevated pulmonary artery pressure and leads to right heart failure. Treatment is focused on targeting the underlying complex etiology via the endothelin, prostacyclin, and nitric oxide (NO) pathways. Emergence of new treatments over the past 2 decades has led to improvement in the functional status and time to clinical worsening. Even with recent advances, outcomes remain suboptimal. Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents. In this review, we summarize the emergence of sildenafil as a treatment for PAH and its role as palliative therapy.

1Department of Medicine, Division of Cardiology, East Tennessee State University, Johnson City, TN; and

2Department of Hospice and Palliative Medicine Wellmont Health System, Kingsport, TN.

Address for correspondence: Assistant Professor, Department of Medicine, 329 N State of Franklin, Johnson City, TN 37604. E-mail:

The authors have no conflicts of interest to declare.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.